<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02764593</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG 3504</org_study_id>
    <secondary_id>RF 3504</secondary_id>
    <secondary_id>CA209-410</secondary_id>
    <nct_id>NCT02764593</nct_id>
  </id_info>
  <brief_title>Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer</brief_title>
  <official_title>Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RTOG Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RTOG Foundation, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety of adding nivolumab to several chemotherapy platforms
      with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>From the first dose of nivolumab to 28 days after the completion of radiation therapy.</time_frame>
    <description>A nivolumab attributable, dose-limiting toxicity (DLT) will be defined as follows:
1) Any ≥ grade 3 adverse event (CTCAE, v. 4) that is related to nivolumab that does not resolve to grade 1 or less within 28 days; 2) A delay in radiotherapy of &gt; 2 weeks due to toxicity related to nivolumab; 3) Inability to complete radiotherapy due to toxicity related to nivolumab; 4) Inability to receive an adequate dose (≥ 70%) of cisplatin (Arm 1 and 2) or cetuximab (Arm 3) due to toxicity definitely related to nivolumab.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma (HNSCC)</condition>
  <arm_group>
    <arm_group_label>Arm 1 (Nivolumab + Cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cisplatin will be given weekly. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (Nivolumab + High-dose Cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Nivolumab via IV administration starting 14 days prior to IMRT, then Day 1 of IMRT and then every 21 days for 6 doses. Cisplatin will be given every 21 days for 3 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 (Nivolumab + Cetuximab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. Cetuximab will be given for 7 doses. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 (Nivolumab + IMRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive Nivolumab via IV administration every 14 days for 10 doses starting 14 days prior to IMRT. IMRT will be given at 5 fractions per week for 7 weeks for a dose of 70 Gy. Adjuvant nivolumab every 28 days for 7 doses will be administered starting 3 months after end of chemoradiation. Adjuvant administration of nivolumab may be discontinued if more than 4 of first 8 patients receive less than 7 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Anti-PD-1 targeted immunotherapy</description>
    <arm_group_label>Arm 1 (Nivolumab + Cisplatin)</arm_group_label>
    <arm_group_label>Arm 2 (Nivolumab + High-dose Cisplatin)</arm_group_label>
    <arm_group_label>Arm 3 (Nivolumab + Cetuximab)</arm_group_label>
    <arm_group_label>Arm 4 (Nivolumab + IMRT)</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Anti-cancer alkylating agent</description>
    <arm_group_label>Arm 1 (Nivolumab + Cisplatin)</arm_group_label>
    <arm_group_label>Arm 2 (Nivolumab + High-dose Cisplatin)</arm_group_label>
    <other_name>Platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Epidermal Growth Factor Receptor (EGFR) antagonist</description>
    <arm_group_label>Arm 3 (Nivolumab + Cetuximab)</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT</intervention_name>
    <description>High-precision radiotherapy</description>
    <arm_group_label>Arm 1 (Nivolumab + Cisplatin)</arm_group_label>
    <arm_group_label>Arm 2 (Nivolumab + High-dose Cisplatin)</arm_group_label>
    <arm_group_label>Arm 3 (Nivolumab + Cetuximab)</arm_group_label>
    <arm_group_label>Arm 4 (Nivolumab + IMRT)</arm_group_label>
    <other_name>Intensity Modulated Radiation Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically-confirmed diagnosis of HNSCC of the oral cavity,
             oropharynx, larynx, or hypopharynx.

          -  Intermediate-risk group: Oropharynx cancer that is p16-positive by
             immunohistochemistry with smoking status &gt; 10 Pack-years, stage T1-2N2b-N3 OR ≤ 10
             pack-years, stage T4N0-N3 or T1-3N3.

          -  High-risk group: Oral cavity, larynx, hypopharynx, or p16-negative oropharynx cancer,
             stage T1-2N2a-N3 or T3-4-N0-3 based on the following diagnostic workup:

               -  Mandatory submission of H&amp;E and p16 stained slides for central review of p16
                  staining is required for oropharyngeal patients and H&amp;E stained slide block (or
                  punch biopsy of paraffin block) for PD-L1 expression analysis for all patients

               -  History/physical examination within 28 days prior to registration

               -  Examination by Radiation Oncologist, Medical Oncologist, and Ear, Nose, Throat
                  (ENT) or Head &amp; Neck Surgeon within 28 days prior to registration

               -  Fiberoptic exam with laryngopharyngoscopy within 28 days prior to registration

               -  Diagnostic quality, cross sectional imaging of the thorax within 28 days prior to
                  registration; 18-F-FDG-PET/CT or conventional CT are acceptable.

               -  Diagnostic quality CT or MRI of neck, with contrast, within 28 days prior to
                  registration; a 18-F-FDG-PET/CT of the neck only is acceptable as a substitute if
                  the CT is of diagnostic quality and with IV contrast.

          -  Age ≥ 18 years

          -  The trial is open to both genders

        Exclusion Criteria:

          -  Definitive clinical or radiologic evidence of distant (beyond cervical lymph node and
             neck tissue) metastatic disease.

          -  Patients with oral cavity cancer are excluded from participation if resection of the
             primary tumor is considered technically feasible by an oral or head and neck cancers
             surgical subspecialist.

          -  Carcinoma of the neck of unknown primary site origin (even if p16-positive).

          -  Absence of RECIST, v. 1.1 defined measurable disease.

          -  Gross total excision of both primary and nodal disease; this includes tonsillectomy,
             local excision of primary site, and nodal excision that removes all clinically and
             radiographically evident disease. Patients with RECIST, v. 1.1 evaluable remaining
             cancer either in the neck or primary site remain eligible.

          -  Simultaneous primary cancers or separate bilateral primary tumor sites.

          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 3 years; (for example, carcinoma in situ of the breast, oral cavity,
             or cervix are all permissible).

          -  Prior systemic chemotherapy for the study cancer.

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields.

          -  Patients with active autoimmune disease, with exceptions of vitiligo, type I diabetes
             mellitus, hypothyroidism and psoriasis.

          -  Use of systemic corticosteroids (&gt; 10 mg daily prednisone or equivalent) or other
             immunosuppressive medications within 14 days of study drug administration, with
             exception of inhaled or topical steroids.

          -  Known immunosuppressive disease, for example HIV infection or history of bone marrow
             transplant or chronic lymphocytic leukemia (CLL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maura Gillison, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTOG Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Ferris, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTOG Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maura Gillison, MD, PhD</last_name>
    <phone>713-792-6363</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Ferris, MD, PhD</last_name>
    <phone>412-623-0327</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Simmons</last_name>
      <phone>650-724-4606</phone>
    </contact>
    <investigator>
      <last_name>A. Dimitrios Colevas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Cancer Center at Orlando Health</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keisha Kortright</last_name>
      <phone>321-841-3812</phone>
    </contact>
    <investigator>
      <last_name>Justin Rineer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Humani-Bundy</last_name>
      <phone>404-778-5720</phone>
    </contact>
    <investigator>
      <last_name>Nabil Saba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Roberts, RN</last_name>
      <phone>502-333-6934</phone>
      <email>tlrobe14@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Neal Dunlap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Perme, RN</last_name>
      <phone>216-844-2512</phone>
    </contact>
    <investigator>
      <last_name>Min Yao, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai He, MD, PhD</last_name>
      <phone>800-293-5066</phone>
    </contact>
    <investigator>
      <last_name>Kai He, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Morris, RN, BSN</last_name>
      <phone>503-215-7503</phone>
    </contact>
    <investigator>
      <last_name>Rom Leidner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC - Shadyside Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Holeva</last_name>
      <phone>412-623-1275</phone>
      <email>holevakd@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>David Clump, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toni Williams</last_name>
      <phone>713-563-2361</phone>
      <email>towilliams@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>David Rosenthal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jeffords</last_name>
      <phone>703-970-6548</phone>
    </contact>
    <investigator>
      <last_name>John Deeken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Kraemer</last_name>
      <phone>608-262-8618</phone>
    </contact>
    <investigator>
      <last_name>Randall Kimple, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2016</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>HNSCC</keyword>
  <keyword>Nivolumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

